|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000122367 |
Summary for LDB3 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000122367 | Gene symbol | LDB3 |
| Gene name | LIM domain binding 3 | |
| HGNC | 15710 | |
| Entrez ID | 11155 | |
| Gene type | protein_coding | |
| Synonyms | LDB3|PDLIM6|KIAA0613|ZASP | |
| UniProtAcc | O75112 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for LDB3 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for LDB3 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for LDB3 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg26338757 | chr10:86668538 | CGI:chr10:86631989-86632485 | UTR,promoter,exon,gene body | 5.01e-01 | 6.04e-01 | -2.59e+00 | 9.63e-03 | 2.63e-02 | -1.03e-01 |
| BRCA | cg14281922 | chr10:86668471 | CGI:chr10:86631989-86632485 | UTR,promoter,exon,gene body | 7.47e-01 | 8.98e-01 | -3.72e+00 | 1.96e-04 | 2.96e-03 | -1.51e-01 |
| BRCA | cg18286285 | chr10:86668490 | CGI:chr10:86631989-86632485 | UTR,promoter,exon,gene body | 6.05e-01 | 8.02e-01 | -3.56e+00 | 3.68e-04 | 4.84e-03 | -1.97e-01 |
| BRCA | cg08300860 | chr10:86668500 | CGI:chr10:86631989-86632485 | UTR,promoter,exon,gene body | 7.40e-01 | 8.53e-01 | -3.27e+00 | 1.08e-03 | 9.87e-03 | -1.13e-01 |
| SARC | cg14281922 | chr10:86668471 | CGI:chr10:86631989-86632485 | UTR,promoter,exon,gene body | 5.64e-01 | 6.79e-01 | -3.77e+00 | 1.61e-04 | 7.74e-04 | -1.15e-01 |
| SARC | cg18286285 | chr10:86668490 | CGI:chr10:86631989-86632485 | UTR,promoter,exon,gene body | 4.71e-01 | 5.73e-01 | -3.42e+00 | 6.26e-04 | 2.41e-03 | -1.02e-01 |
| ACC | cg18286285 | chr10:86668490 | CGI:chr10:86631989-86632485 | UTR,promoter,exon,gene body | 6.72e-01 | 7.99e-01 | -2.14e+00 | 3.25e-02 | 4.27e-02 | -1.26e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| HNSC | cg14281922 | chr10:86668471 | CGI:chr10:86631989-86632485 | UTR,promoter,exon,gene body | 6.30e-01 | 7.35e-01 | -3.20e+00 | 1.37e-03 | 2.37e-03 | -1.04e-01 |
| LUSC | cg00458754 | chr10:86668056 | CGI:chr10:86631989-86632485 | promoter | 5.58e-01 | 6.64e-01 | -2.38e+00 | 1.72e-02 | 2.11e-02 | -1.06e-01 |
| LIHC | cg26338757 | chr10:86668538 | CGI:chr10:86631989-86632485 | UTR,promoter,exon,gene body | 4.68e-01 | 6.15e-01 | -4.66e+00 | 3.14e-06 | 9.96e-06 | -1.46e-01 |
| LIHC | cg11776930 | chr10:86667643 | CGI:chr10:86631989-86632485 | promoter | 6.91e-01 | 8.37e-01 | -6.33e+00 | 2.47e-10 | 4.63e-09 | -1.46e-01 |
| LIHC | cg09138865 | chr10:86667678 | CGI:chr10:86631989-86632485 | promoter | 7.45e-01 | 8.71e-01 | -6.12e+00 | 9.27e-10 | 1.23e-08 | -1.26e-01 |
| LIHC | cg12008118 | chr10:86668672 | CGI:chr10:86631989-86632485 | UTR,promoter,exon,gene body | 6.85e-01 | 8.01e-01 | -6.40e+00 | 1.53e-10 | 3.27e-09 | -1.17e-01 |
| CHOL | cg19286437 | chr10:86668360 | CGI:chr10:86631989-86632485 | promoter | 4.52e-01 | 6.87e-01 | -2.51e+00 | 1.22e-02 | 2.39e-02 | -2.34e-01 |
| CHOL | cg22715761 | chr10:86668390 | CGI:chr10:86631989-86632485 | promoter | 4.83e-01 | 6.00e-01 | -2.58e+00 | 9.87e-03 | 2.15e-02 | -1.17e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| THCA | cg19286437 | chr10:86668360 | CGI:chr10:86631989-86632485 | promoter | 3.09e-01 | 4.36e-01 | -4.95e+00 | 7.33e-07 | 4.71e-06 | -1.27e-01 |
| COAD | cg26338757 | chr10:86668538 | CGI:chr10:86631989-86632485 | UTR,promoter,exon,gene body | 5.15e-01 | 6.46e-01 | -3.25e+00 | 1.15e-03 | 3.29e-03 | -1.30e-01 |
| COAD | cg14281922 | chr10:86668471 | CGI:chr10:86631989-86632485 | UTR,promoter,exon,gene body | 6.78e-01 | 7.87e-01 | -2.89e+00 | 3.89e-03 | 7.92e-03 | -1.09e-01 |
| COAD | cg18286285 | chr10:86668490 | CGI:chr10:86631989-86632485 | UTR,promoter,exon,gene body | 6.11e-01 | 7.38e-01 | -2.77e+00 | 5.68e-03 | 1.04e-02 | -1.27e-01 |
| BLCA | cg19286437 | chr10:86668360 | CGI:chr10:86631989-86632485 | promoter | 2.80e-01 | 3.93e-01 | -2.13e+00 | 3.34e-02 | 3.80e-02 | -1.13e-01 |
| BLCA | cg22715761 | chr10:86668390 | CGI:chr10:86631989-86632485 | promoter | 3.80e-01 | 5.03e-01 | -2.39e+00 | 1.70e-02 | 2.44e-02 | -1.24e-01 |
| BLCA | cg14281922 | chr10:86668471 | CGI:chr10:86631989-86632485 | UTR,promoter,exon,gene body | 5.37e-01 | 6.61e-01 | -2.06e+00 | 3.91e-02 | 4.23e-02 | -1.24e-01 |
| KIRP | cg26338757 | chr10:86668538 | CGI:chr10:86631989-86632485 | UTR,promoter,exon,gene body | 5.89e-01 | 4.67e-01 | 2.64e+00 | 8.20e-03 | 1.48e-02 | 1.22e-01 |
Top |
Exon skipping events with PSI in TCGA for LDB3 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for LDB3 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for LDB3 |
| TFs related to LDB3. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| ACC | ZNF519 | LDB3 | 3.87e+00 | 9.82e-01 | 2.81e+00 | 3.02e-03 | Male-biased |
| ACC | ZNF792 | LDB3 | 3.83e+00 | 9.81e-01 | 2.80e+00 | 3.46e-03 | Male-biased |
| BRCA | CDX2 | LDB3 | 4.39e+00 | 9.85e-01 | 2.98e+00 | 5.71e-03 | Male-biased |
| BRCA | EVX2 | LDB3 | 4.58e+00 | 9.83e-01 | 3.35e+00 | 1.00e-02 | Male-biased |
| BRCA | POU2F2 | LDB3 | 4.76e+00 | 9.87e-01 | 3.43e+00 | 7.47e-03 | Male-biased |
| BRCA | RBAK | LDB3 | 2.78e+00 | 4.20e-03 | 4.26e+00 | 9.80e-01 | Female-biased |
| BRCA | SOX4 | LDB3 | 4.57e+00 | 9.87e-01 | 3.20e+00 | 6.52e-03 | Male-biased |
| BRCA | ZIC2 | LDB3 | 2.11e+00 | 6.49e-04 | 4.18e+00 | 9.82e-01 | Female-biased |
| BRCA | ZNF101 | LDB3 | 2.63e+00 | 1.95e-03 | 4.36e+00 | 9.85e-01 | Female-biased |
| BRCA | ZNF157 | LDB3 | 3.36e+00 | 9.28e-03 | 4.59e+00 | 9.82e-01 | Female-biased |
| BRCA | ZNF19 | LDB3 | 2.76e+00 | 2.20e-03 | 4.45e+00 | 9.87e-01 | Female-biased |
| BRCA | ZNF28 | LDB3 | 2.26e+00 | 2.54e-04 | 4.60e+00 | 9.92e-01 | Female-biased |
| BRCA | ZNF320 | LDB3 | 2.10e+00 | 5.81e-04 | 4.20e+00 | 9.82e-01 | Female-biased |
| BRCA | ZNF322 | LDB3 | 2.42e+00 | 1.48e-03 | 4.23e+00 | 9.82e-01 | Female-biased |
| BRCA | ZNF331 | LDB3 | 2.34e+00 | 6.19e-04 | 4.43e+00 | 9.88e-01 | Female-biased |
| BRCA | ZNF37A | LDB3 | 2.72e+00 | 2.20e-03 | 4.41e+00 | 9.86e-01 | Female-biased |
| BRCA | ZNF394 | LDB3 | 2.53e+00 | 1.94e-03 | 4.25e+00 | 9.82e-01 | Female-biased |
| BRCA | ZNF419 | LDB3 | 2.67e+00 | 2.66e-03 | 4.29e+00 | 9.83e-01 | Female-biased |
| BRCA | ZNF431 | LDB3 | 2.86e+00 | 2.73e-03 | 4.48e+00 | 9.87e-01 | Female-biased |
| BRCA | ZNF530 | LDB3 | 2.25e+00 | 8.16e-04 | 4.25e+00 | 9.84e-01 | Female-biased |
| BRCA | ZNF534 | LDB3 | 2.88e+00 | 2.92e-03 | 4.48e+00 | 9.87e-01 | Female-biased |
| BRCA | ZNF573 | LDB3 | 2.98e+00 | 4.70e-03 | 4.42e+00 | 9.84e-01 | Female-biased |
| BRCA | ZNF605 | LDB3 | 2.49e+00 | 1.09e-03 | 4.40e+00 | 9.87e-01 | Female-biased |
| BRCA | ZNF682 | LDB3 | 2.11e+00 | 6.29e-04 | 4.18e+00 | 9.82e-01 | Female-biased |
| BRCA | ZNF708 | LDB3 | 3.19e+00 | 8.77e-03 | 4.44e+00 | 9.80e-01 | Female-biased |
| BRCA | ZNF816 | LDB3 | 2.58e+00 | 1.09e-03 | 4.49e+00 | 9.89e-01 | Female-biased |
| BRCA | ZNF860 | LDB3 | 2.47e+00 | 8.37e-04 | 4.47e+00 | 9.89e-01 | Female-biased |
| BRCA | ZNF891 | LDB3 | 2.70e+00 | 1.21e-03 | 4.59e+00 | 9.90e-01 | Female-biased |
| GBM | ZFX | LDB3 | 2.84e+00 | 5.84e-03 | 4.09e+00 | 9.82e-01 | Female-biased |
| GBM | ZIC2 | LDB3 | 2.91e+00 | 5.76e-03 | 4.17e+00 | 9.84e-01 | Female-biased |
| GBM | ZNF101 | LDB3 | 3.17e+00 | 9.21e-03 | 4.25e+00 | 9.82e-01 | Female-biased |
| GBM | ZNF19 | LDB3 | 3.23e+00 | 1.03e-02 | 4.26e+00 | 9.81e-01 | Female-biased |
| GBM | ZNF28 | LDB3 | 2.96e+00 | 4.31e-03 | 4.34e+00 | 9.88e-01 | Female-biased |
| GBM | ZNF331 | LDB3 | 3.17e+00 | 9.99e-03 | 4.22e+00 | 9.80e-01 | Female-biased |
| GBM | ZNF534 | LDB3 | 3.09e+00 | 8.92e-03 | 4.18e+00 | 9.81e-01 | Female-biased |
| GBM | ZNF573 | LDB3 | 3.31e+00 | 7.71e-03 | 4.47e+00 | 9.86e-01 | Female-biased |
| GBM | ZNF605 | LDB3 | 3.19e+00 | 9.78e-03 | 4.25e+00 | 9.81e-01 | Female-biased |
| GBM | ZNF708 | LDB3 | 3.49e+00 | 1.18e-02 | 4.48e+00 | 9.82e-01 | Female-biased |
| GBM | ZNF816 | LDB3 | 3.04e+00 | 6.57e-03 | 4.26e+00 | 9.84e-01 | Female-biased |
| GBM | ZNF860 | LDB3 | 3.05e+00 | 6.77e-03 | 4.26e+00 | 9.84e-01 | Female-biased |
| GBM | ZNF891 | LDB3 | 3.08e+00 | 6.19e-03 | 4.32e+00 | 9.86e-01 | Female-biased |
| MESO | CDX2 | LDB3 | 4.52e+00 | 9.83e-01 | 3.34e+00 | 1.07e-02 | Male-biased |
| LDB3 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for LDB3 |
| RBPs related to ES in LDB3. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| LDB3 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs11189736 | chr10:81407634:T:G | - | 0.143286009846388 | 0.000131385732074798 | HNSC | Female-baised eQTL |
| rs11202230 | chr10:86859211:T:C | - | 0.137262716379545 | 0.0233287962244953 | SARC | Female-baised eQTL |
| rs80299163 | chr10:86759239:C:T | - | 0.13382832852399 | 0.0491373552629088 | SARC | Female-baised eQTL |
| rs140745739 | chr10:86756333:G:C | - | 0.138160310415647 | 0.0497171658112647 | SARC | Female-baised eQTL |
| rs4933409 | chr10:86763882:C:G | - | 0.138160310415647 | 0.0497171658112647 | SARC | Female-baised eQTL |
| rs11201358 | chr10:85087278:G:A | - | 0.131240197678945 | 0.00720153025172153 | STAD | Female-baised eQTL |
| rs7072281 | chr10:85100291:C:A | - | 0.131240197678945 | 0.00720153025172153 | STAD | Female-baised eQTL |
| rs12250852 | chr10:85106823:G:A | - | 0.131240197678945 | 0.00720153025172153 | STAD | Female-baised eQTL |
| rs1538673 | chr10:85101874:A:G | - | 0.130741943411306 | 0.00795068550104136 | STAD | Female-baised eQTL |
| rs11201374 | chr10:85101431:C:T | - | 0.126157763114187 | 0.0117748312129754 | STAD | Female-baised eQTL |
| rs12248262 | chr10:85090574:G:A | - | 0.125662330378416 | 0.0155868494491669 | STAD | Female-baised eQTL |
| rs7923748 | chr10:85092375:G:A | - | 0.125662330378416 | 0.0155868494491669 | STAD | Female-baised eQTL |
| rs17370064 | chr10:85165072:G:T | - | 0.124279396150251 | 0.0156193902116542 | STAD | Female-baised eQTL |
| rs2095936 | chr10:85168827:G:A | - | 0.124279396150251 | 0.0156193902116542 | STAD | Female-baised eQTL |
| rs12768874 | chr10:85169787:C:T | - | 0.124279396150251 | 0.0156193902116542 | STAD | Female-baised eQTL |
| rs35672874 | chr10:85170778:C:T | - | 0.124279396150251 | 0.0156193902116542 | STAD | Female-baised eQTL |
| rs28832301 | chr10:85157741:C:A | - | 0.120307147006918 | 0.0177896045914878 | STAD | Female-baised eQTL |
| rs12780140 | chr10:85159246:A:C | - | 0.120307147006918 | 0.0177896045914878 | STAD | Female-baised eQTL |
| rs34596922 | chr10:85160429:A:T | - | 0.120307147006918 | 0.0177896045914878 | STAD | Female-baised eQTL |
| rs17369480 | chr10:85143382:T:G | - | 0.119178740602623 | 0.0203810195415776 | STAD | Female-baised eQTL |
| rs75347336 | chr10:85184451:C:G | - | 0.141178612455776 | 0.0279173268842608 | STAD | Female-baised eQTL |
| rs10509510 | chr10:85145077:C:A | - | 0.115185567158805 | 0.0286397643253589 | STAD | Female-baised eQTL |
| rs12762398 | chr10:85152881:A:G | - | 0.115185567158805 | 0.0286397643253589 | STAD | Female-baised eQTL |
| rs12251979 | chr10:85115694:T:C | - | 0.11325098518923 | 0.0301268268054429 | STAD | Female-baised eQTL |
| rs12269226 | chr10:85121201:G:C | - | 0.11325098518923 | 0.0301268268054429 | STAD | Female-baised eQTL |
| rs10466163 | chr10:85123611:G:A | - | 0.11325098518923 | 0.0301268268054429 | STAD | Female-baised eQTL |
| rs11201396 | chr10:85125998:C:T | - | 0.11325098518923 | 0.0301268268054429 | STAD | Female-baised eQTL |
| rs149355856 | chr10:85128010:A:G | - | 0.11325098518923 | 0.0301268268054429 | STAD | Female-baised eQTL |
| rs12240506 | chr10:85114401:C:T | - | 0.113093223276742 | 0.0303809795332877 | STAD | Female-baised eQTL |
| rs12258464 | chr10:85119370:A:G | - | 0.109036752377878 | 0.0444972111934087 | STAD | Female-baised eQTL |
| rs2484451 | chr10:82698486:G:A | - | -0.110770942358525 | 0.00462232024901361 | LGG | Female-baised eQTL |
| rs1889707 | chr10:82701107:T:A | - | -0.110770942358525 | 0.00462232024901361 | LGG | Female-baised eQTL |
| rs2249968 | chr10:82692211:T:C | - | -0.110874989457274 | 0.00465445093741969 | LGG | Female-baised eQTL |
| rs2246280 | chr10:82700766:C:G | - | -0.107732584057528 | 0.00683299382022299 | LGG | Female-baised eQTL |
| rs2820113 | chr10:82703234:T:A | - | -0.107732584057528 | 0.00683299382022299 | LGG | Female-baised eQTL |
| rs2494028 | chr10:82705406:T:C | - | -0.107732584057528 | 0.00683299382022299 | LGG | Female-baised eQTL |
| rs2250544 | chr10:82688071:T:C | - | -0.107835946684675 | 0.00687702227161726 | LGG | Female-baised eQTL |
| rs2250431 | chr10:82688521:G:T | - | -0.107835946684675 | 0.00687702227161726 | LGG | Female-baised eQTL |
| rs2249842 | chr10:82693579:T:C | - | -0.107835946684675 | 0.00687702227161726 | LGG | Female-baised eQTL |
| rs2265975 | chr10:82693831:A:G | - | -0.107835946684675 | 0.00687702227161726 | LGG | Female-baised eQTL |
| rs2246880 | chr10:82695443:A:G | - | -0.107835946684675 | 0.00687702227161726 | LGG | Female-baised eQTL |
| rs2246386 | chr10:82700137:T:C | - | -0.10769669772735 | 0.00693135936132047 | LGG | Female-baised eQTL |
| rs2246165 | chr10:82701874:C:A | - | -0.104890660765888 | 0.00994880409423155 | LGG | Female-baised eQTL |
| rs2484454 | chr10:82706128:G:A | - | -0.10589447058489 | 0.0106165359773634 | LGG | Female-baised eQTL |
| rs2246622 | chr10:82697770:T:C | - | -0.104307198398941 | 0.0107780679087494 | LGG | Female-baised eQTL |
| rs2494027 | chr10:82698473:C:T | - | -0.104307198398941 | 0.0107780679087494 | LGG | Female-baised eQTL |
| rs915344 | chr10:82701221:A:T | - | -0.104307198398941 | 0.0107780679087494 | LGG | Female-baised eQTL |
| rs2484453 | chr10:82705896:G:A | - | -0.104307198398941 | 0.0107780679087494 | LGG | Female-baised eQTL |
| rs2250313 | chr10:82689407:G:A | - | -0.104408468075008 | 0.0108463570604602 | LGG | Female-baised eQTL |
| rs2246879 | chr10:82695446:C:T | - | -0.104408468075008 | 0.0108463570604602 | LGG | Female-baised eQTL |
| rs2250828 | chr10:82685619:G:C | - | -0.103851691787559 | 0.0118736710465096 | LGG | Female-baised eQTL |
| rs2265974 | chr10:82685635:A:T | - | -0.103851691787559 | 0.0118736710465096 | LGG | Female-baised eQTL |
| rs2250933 | chr10:82684829:C:A | - | -0.0998141059503952 | 0.0181528425308717 | LGG | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs1051070 | chr10:89015015:A:T | - | 0.0909475383800836 | 0.0360159078009536 | SARC | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000122367 |
| CpG Site: cg22715761 | |
| Position to Gene: promoter | |
| Male Effect: - | |
| Female Effect: -0.304996010483795 | |
 | Gene ID: ENSG00000122367 |
| CpG Site: cg19286437 | |
| Position to Gene: promoter | |
| Male Effect: - | |
| Female Effect: -0.260284617187039 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg22715761 | chr10:86668390 | promoter | -0.304996010483795 | 1.66257620468259e-05 | -0.42765478566722726 | 1.2282359609213236e-07 | SARC |
| cg19286437 | chr10:86668360 | promoter | -0.260284617187039 | 5.74912421923036e-05 | -0.3875023528199374 | 1.5999225774788408e-06 | SARC |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of LDB3 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000122367 | LDB3 | C1832244 | CARDIOMYOPATHY, DILATED, 1C (disorder) | 1 | CTD_human |
| ENSG00000122367 | LDB3 | C2678065 | Myofibrillar Myopathy | 1 | CTD_human |
